Résultats annuels consolidés au 31 mars 2026

S.T. Dupont reports FY 2025-26 revenue of €55.8m (down 1.8% y/y; +0.6% organic), with FX the main drag (-2.4% reported impact). Operating profit improved to €2.8m from €2.5m, but net income fell to €2.0m from €3.4m as the prior year benefited from a higher income tax position (€1.4m vs €0.2m). Net cash declined to €2.5m from €5.6m, attributed to higher inventory ahead of key launches (26/27) and slower-than-expected receivables.

Analysis

The key issue is not the modest top-line swing; it is that the business is still converting accounting profit into very little balance-sheet flexibility. A net cash position of only a few million euros against a highly seasonal brand with working-capital needs leaves the equity exposed to any slip in sell-through, especially if the upcoming launch cycle disappoints or if receivables keep aging. The market should treat this as a liquidity-quality story first and a brand story second.

The mix is also subtly worse than the aggregate suggests. Strength in high-margin legacy products and licensing is being partially offset by channel rationalization, FX, and weaker controlled distribution, which usually means less visibility and more dependence on wholesalers. That matters because a shift toward agents/distributors can support reported revenue in the near term while masking weaker pricing power and lower control over inventory, making any rebound more fragile over the next 1-3 quarters.

The contrarian point: the consensus may be underestimating how much of the apparent resilience is timing-related rather than structural. The inventory build ahead of launches can help future sales, but if sell-through is soft, the company will be forced into discounting or slower replenishment, which would pressure gross margin and cash again within 6-18 months. The clean falsifier is cash conversion: if working capital does not reverse by the next reporting cycle and net cash stays around current levels or lower, the equity should continue to de-rate versus better-capitalized luxury names.

Key Decisions for Investors

• No immediate directional trade in the name; wait for the next quarter to confirm that receivables days and inventory days are falling. If net cash does not re-expand above ~€4m, treat the stock as a balance-sheet trap rather than a value opportunity.
• For luxury exposure, prefer long LVMH (MC.PA) and Richemont (CFR.SW) over subscale branded goods players: both have better pricing power, stronger cash generation, and less reliance on wholesale/channel management. Use a 1-3 month horizon and keep the thesis invalidated if Asia sales momentum rolls over broadly.
• If you want a relative-value expression on weaker luxury execution, short Kering (KER.PA) against long LVMH (MC.PA) rather than betting on this microcap; the cleaner balance sheet should compound better if China/Middle East demand is only modestly improving. Falsifier: any sharp rebound in Kering sell-through or margin guidance.
• Set an alert for the next earnings release: if the company signals another stock build, slower collections, or any need to protect cash via lower capex/dividends, the equity risk premium should widen further. That would be the point to consider a short or a put structure if liquidity allows.